Date: <u>May 7th, 2021</u>					
Your Name: <u>Min Qin</u>					
Manuscript Title: Using immune-related IncRNAs to construct novel biomarkers and investigate the immune					
andscape of breast cancer.					
Vanuscript number (if known):					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	√None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> _None	
	testimony		
_	0		
7	Support for attending meetings and/or travel	<u>√</u> _None	
8	Patents planned, issued or	_ <u>√</u> None	
	pending		
9	Participation on a Data	√ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>√</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_ <u>√</u> None	
12	Receipt of equipment,	_ <u>√</u> None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_ <u>√</u> _None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
	Dr. Qin has nothing to disclose.		

Date: May 7th, 2021	
Your Name: <u>Yanfei Ma</u>	
Manuscript Title: Using immune	-related IncRNAs to construct novel biomarkers and investigate the immune
landscape of breast cancer.	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	None	
4	Consulting fees	√_ None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending	√ None	
/	meetings and/or travel	<u>√</u> _None	
8	Patents planned, issued or	_ <u>√</u> None	
	pending		
9	Participation on a Data	_√ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_ <u>√</u> None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ <u>√</u> None	
12	Receipt of equipment,	_√ None	
12	materials, drugs, medical	<u>v</u> None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_ <u>√</u> _None	
	illialiciai liiterests		
	ease summarize the above control of the control of		ollowing box:

Date: May 7th, 20	<u>21 </u>
Your Name: Zifa	ın Wang
Manuscript Title:	Using immune-related IncRNAs to construct novel biomarkers and investigate the immune
landscape of breast	cancer.
Manuscript number	(if known):
_	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	<u>√</u> _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	_√ None	
	testimony		
	•		
7	Support for attending meetings and/or travel	<u>√</u> _None	
8	Patents planned, issued or	_ <u>√</u> None	
	pending		
0	D		
9	Participation on a Data Safety Monitoring Board or	_ <u>√</u> None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ <u>√</u> None	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_ <u>√</u> _None	
	financial interests		
	ase summarize the above control of the summarize the summarize the summarize the above control of the summarize th		llowing box:

Date:May 7th, 2021_				
Your Name: <u>Dalang Fang</u>				
Manuscript Title:Using immune-related IncRNAs to construct novel biomarker	s and investigate the immune			
landscape of breast cancer.				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	None	
4	Consulting fees	√_ None	

5	Payment or honoraria for	<u>√</u> _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	_√ None	
	testimony		
	•		
7	Support for attending meetings and/or travel	<u>-</u> _None	
8	Patents planned, issued or	_ <u>√</u> None	
	pending		
9	Participation on a Data	_ <u>√</u> None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	√ None	
10	in other board, society,	<u>v</u> None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ <u>√</u> None	
12	Receipt of equipment,	_ <u>√</u> None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	<u>√</u> None	
	financial interests		
	ase summarize the above co		llowing box:

Date:May 7th, 2021	
Your Name:	
Manuscript Title: Using immune-related IncRNAs to construct novel biomarkers and investigate the imm	nune
landscape of breast cancer.	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None		
Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	None		
3	Royalties or licenses	None		
4	Consulting fees	None		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>√</u> _None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>√</u> None	
13	Other financial or non- financial interests	_ <u>√</u> None	
	Pase summarize the above control of the control of		ollowing box: